Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 869-870

  Groeneveldt, Joanne A ^a   Gans, Steven J M ^b   Bogaard, Harm J ^a   Vonk Noordegraaf, Anton ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dept of Pulmonary Diseases ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PHOSPHODIESTERASE V; SILDENAFIL;

ADULT; ANKLE EDEMA; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART CATHETERIZATION; HEART FAILURE; HUMAN; LETTER; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; UNSPECIFIED SIDE EFFECT;

HUMANS; POTASSIUM CHANNELS; PULMONARY ARTERY; SRC-FAMILY KINASES;

EID: 84883528181     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00035913     Document Type: Letter

References (5)

1. Nagaraj C, Tang B, Bálint Z, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.
2. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
3. Voelkel NF, Gomez-Arroyo J, Abbate A, et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012; 40: 1555-1565.
4. Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J 2011; 38: 218-220.
5. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004; 141: 169-177.